GlassScriptPhysician profile
Steven L Lyndaker
NPI 1912992595
$7,478.18
in general payments reported to CMS, 2019-2025
39 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $686 · 2021: $1,036 · 2022: $1,192 · 2023: $1,251 · 2024: $1,443 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,774 · Education: $18.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.75 |
| Education | $18.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $937.28 | 2021-2025 | |
| Novo Nordisk INC | $895.60 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $636.04 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $574.47 | 2019-2025 | |
| Amgen INC. | $479.72 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.29 | 2019-2025 | Synjardy, Jardiance |
| Lilly USA, LLC | $458.21 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $386.44 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $376.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $305.19 | 2019-2025 | Gardasil 9, Vaxelis, Verquvo |
| Sanofi-Aventis U.S. LLC | $233.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $159.94 | 2019-2022 | |
| Exact Sciences Corporation | $149.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $148.44 | 2022-2025 | Rexulti |
| Amarin Pharma, INC. | $134.81 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lyndaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.